{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Time from entry into trial until death of any cause. Participants who were alive at the time of the analysis were censored at the date of the last follow-up assessment. Participants without follow-up assessment were censored at the day of last dose and participants with no post baseline information were censored at the baseline date.","groups":[{"description":"Participants received single doses of rituximab 750 mg/m\\^2 IV at Weeks 1 through 5, and 7, 9, 11, 14, 16, 18, 20, and 22; cytarabine 2 g/m\\^2 IV every 24 hours for 2 doses at Weeks 11 and 22; and single doses of MTX 8 g/m\\^2 IV at Weeks 3, 5, 7, 9, 14, 16, 18, and 20.","id":"OG000","title":"Rituximab, Cytarabine, and MTX"}],"populationDescription":"Due to early study termination, all efficacy data were documented by data listings only, no data analysis was performed.","reportingStatus":"POSTED","timeFrame":"Time of last follow-up assessment between Day 1 and 3 years","title":"Overall Survival","type":"SECONDARY"}